Novacap acquires PCI Synthesis to expand offering in the US

By Melissa Fassbender contact

- Last updated on GMT

Novacap acquires PCI Synthesis to expand offering in the US
France-based Novacap is set to acquire PCI Synthesis – a CDMO located near Boston’s biotech hub – to expand its pharmaceutical offerings in the US.

Following the transaction, terms of which were not disclosed, the contract development and manufacturing organization (CDMO) PCI Synthesis will become a wholly owned subsidiary of Novacap.

PCI’s existing management have signed long-term contracts and will remain in place.

“The acquisition of PCI Synthesis perfectly fits with our strategic roadmap as it will strengthen our offering to the pharmaceutical industry and provide Novacap with a strong and innovative platform to accelerate our development in the US,”​ said Pierre Luzeau, CEO of Novacap in a press release.

“The two companies operate complementary CDMO activities and share common values such as entrepreneurship, operational excellence and dedication to customer satisfaction,”​ he added.

Ed Price, founder and president of PCI Synthesis said in a blog post on the company’s website​ that the Boston-based CDMO will be the lead US company for Novacap.

With the acquisition, Price said it is creating a CDMO which can offer a range of services with access to Novacap’s PCAS facilities in France and its Uetikon facility in Germany.

PCI also will have access to Novacap’s “additional chemistry expertise, solid state chemistry development, dual site processing, and substantial additional capacity for the commercialization of the next generation of Life Science products,” ​he said.

Related products

show more

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

INDENA ALWAYS AT THE FOREFRONT FOR CDMO SERVICES

Indena | 25-Oct-2022 | Technical / White Paper

Indena is well known in the space of naturally derived molecules, with a know-how developed over its one hundred year history. At the same time, the company...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Related suppliers

Follow us

Products

View more

Webinars